| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780019 | Gynecologic Oncology | 2018 | 8 Pages |
Abstract
A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. Molecular and treatment factors are discussed.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Allison A. Gockley, David L. Kolin, Christopher S. Awtrey, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos,